11 / 18
Page 42
O c t o b e r 1 9 - 2 0 , 2 0 1 8 | T o k y o , J a p a n
Pharma Congress 2018 & Molecular Medicine 2018
& Psychiatric Disorders 2018
Asian Journal of Biomedical and Pharmaceutical Sciences
|
ISSN: 2249-622X
|
Volume 8
International Conference on
PHARMACEUTICS AND NOVEL DRUG DELIVERY SYSTEMS
19
th
International Conference on
CELLULAR AND MOLECULAR MEDICINE
19
th
Annual Congress on
PSYCHIATRY AND PSYCHIATRIC DISORDERS
&
&
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
alliedacademies.comYEARS
Asian J Biomed Pharmaceut Sci 2018, Volume 8 | DOI: 10.4066/2249-622X-C3-009
BREAST CANCER AND BMI: ROLE OF L-CARNITINE IN PREDICTION OF
ANSWER TO TREATMENT AND OUTCOME OF TUMOR IN PATIENTS WITH
OBESITY
Hojouj M I M
Dnipropetrovsk Medical Academy, Ukraine
I
ncreasing the effectiveness of antitumor therapy in breast cancer patients who take L-carnitine during preoperative systemic
antitumor therapy compared with patients receiving standard neoadjuvant systemic antitumor therapy served as a prerequisite
for studying possi-ble antitumor mechanisms of L-carnitine. The positive effect of L-carnitine is due to the trans-fer of palm-n-fatty
acid through the inner membrane into the mitochondrial matrix, which contributes to the formation of a significant number of ATP
molecules. It has also been shown that L-carnitine can have a double protective effect, enhancing the energy dynamics of the cell
and inhibiting the hyperexcitability of the cell membrane, making it an ideal tool for the prevention and treatment of complications
of antitumor therapy and concomitant metabolic disorders. This work summarizes the results of epidemiological and clinical stud-
ies on the use of L-carnitine in the treatment of breast cancer.